English
French
English
French
About Us
Operations
Our Products
Programs
Contact
NATCO transfers Lenalidomide ANDA to Arrow
Home
NATCO Global
NATCO transfers Lenalidomide ANDA to Arrow
August 4, 2021
natcopharma-wpdmn
No Comments
NATCO transfers Lenalidomide ANDA to Arrow
Read more >
Prev Post
NATCO receives approval for Carfilzomib Vials ANDA (generic for KYPROLIS
®
) in the US market
Next Post
Natco Pharma (Canada) Inc. announces the launch of
Pr
NAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid
®
Leave a Reply
Cancel reply
Your name *
Your email *
Save my name, email, and website in this browser for the next time I comment.
Comments *
Post Comment
×
